AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

12.590

+0.1601.29%

Volume:1.20M

Turnover:15.06M

Market Cap:1.60B

PE:11.59

High:12.730

Open:12.600

Low:12.265

Close:12.430

Loading ...

Overview Company News Filings

Neuren Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

News Flash: 6 Analysts Think Neuren Pharmaceuticals Limited (ASX:NEU) Earnings Are Under Threat

Simply Wall St.

Neuren Pharmaceuticals Receives First Milestone Payment for Rett Syndrome Drug; Shares Down 6%

MT Newswires Live

BRIEF-Neuren Pharmaceuticals Receives First Daybue Sales Milestone Payment

Neuren Pharmaceuticals Ltd - Neuren Receives First Daybue Sales Milestone Payment of US$50 Mln

THOMSON REUTERS

Neuren Pharmaceuticals Posts Lower 2024 Earnings as Revenue Drops

MT Newswires Live

Neuren Pharmaceuticals Posts 2024 EPS of AU$1.0861, Revenue of AU$227.8 Million

MT Newswires Live

Neuren Pharmaceuticals FY Net Income AUD 24.2 Million

THOMSON REUTERS

Here are the top 10 ASX 200 shares today

Neuren Pharmaceuticals Partner Posts 97% Surge in Rett Syndrome Drug Sales in 2024; Neuren Shares Up 8%

MT Newswires Live

Neuren Pharmaceuticals' (ASX:NEU) investors will be pleased with their massive 712% return over the last five years

Simply Wall St.

Here are the top 10 ASX 200 shares today

Neuren Receives New US FDA Rare Pediatric Disease Designation for Neurodevelopmental Disorder Drug Candidate; Shares Up 6%

MT Newswires Live

BRIEF-Neuren Pharmaceuticals Gets Rare Pediatric Disease Designation From US FDA

BUZZ-Australia's Neuren Pharmaceuticals climbs to two-week high on US FDA designation

Neuren Pharmaceuticals - Neuren Receives Rare Pediatric Disease Designation From US FDA

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NEU.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":12.59,"timestamp":1741237920000,"preClose":12.43,"halted":0,"volume":1198634,"delay":0,"changeRate":0.012872,"change":0.16,"floatShares":110014206,"shares":127012624,"eps":1.086099,"lyrEps":1.111713,"pbRate":4.39,"amount":15058600,"amplitude":0.037409,"volumeRatio":1.467186,"dividePrice":0,"prevYearClose":12.5,"fiveDayClose":14.2,"twentyDayClose":13.93},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":110014206,"roa":"34.05%","roe":"49.92%","lyrEps":1.111713,"volumeRatio":1.467186,"shares":127012624,"dividePrice":0,"high":12.73,"amplitude":0.037409,"preClose":12.43,"low":12.265,"week52Low":10.9,"pbRate":"4.39","psRate":"7.37","week52High":24,"institutionHeld":0,"latestPrice":12.59,"eps":1.086099,"divideRate":0,"volume":1198634,"delay":0,"ttmEps":1.086099,"open":12.6,"prevYearClose":12.5,"prevWeekClose":13.23,"prevMonthClose":13.23,"prevQuarterClose":12.5,"fiveDayClose":14.2,"twentyDayClose":13.93,"sixtyDayClose":12.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517198674","title":"Neuren Pharmaceuticals Full Year 2024 Earnings: Beats Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2517198674","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517198674?lang=en_us&edition=fundamental","pubTime":"2025-03-05 04:52","pubTimestamp":1741121564,"startTime":"0","endTime":"0","summary":"ASX:NEU Revenue and Expenses Breakdown March 4th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 13%. Earnings per share  also surpassed analyst estimates by 21%.In the last 12 months, the only revenue segment was Commercial Products contributing AU$213.2m. The most substantial expense, totaling AU$37.1m were related to Non-Operating costs. This indicates that a significant portion of the company's costs is related to non-core activities. Explore how NEU's revenue and expenses shape its earnings.Looking ahead, revenue is expected to decline by 11% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Australia are expected to grow by 44%.The company's shares are down 7.9% from a week ago.It is worth noting though that we have found 1 warning sign for Neuren Pharmaceuticals that you need to take into consideration.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuren-pharmaceuticals-full-2024-earnings-205244548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NEU.AU"],"gpt_icon":0},{"id":"2516158562","title":"News Flash: 6 Analysts Think Neuren Pharmaceuticals Limited (ASX:NEU) Earnings Are Under Threat","url":"https://stock-news.laohu8.com/highlight/detail?id=2516158562","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516158562?lang=en_us&edition=fundamental","pubTime":"2025-03-02 06:42","pubTimestamp":1740868953,"startTime":"0","endTime":"0","summary":"The analysts covering Neuren Pharmaceuticals Limited  delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Both revenue and earnings per share  forecasts went under the knife, suggesting analysts have soured majorly on the business.Following the latest downgrade, the current consensus, from the six analysts covering Neuren Pharmaceuticals, is for revenues of AU$66m in 2025, which would reflect a stressful 66% reduction in Neuren Pharmaceuticals' sales over the past 12 months. Statutory earnings per share are anticipated to dive 72% to AU$0.26 in the same period. Prior to this update, the analysts had been forecasting revenues of AU$122m and earnings per share  of AU$0.35 in 2025. It looks like analyst sentiment has declined substantially, with a sizeable cut to revenue estimates and a pretty serious decline to earnings per share numbers as well.ASX:NEU Earnings and Revenue Growth March 1st 2025. Of course, se","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/news-flash-6-analysts-think-224233508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NEU","NEU.AU"],"gpt_icon":0},{"id":"2514024361","title":"Neuren Pharmaceuticals Receives First Milestone Payment for Rett Syndrome Drug; Shares Down 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514024361","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514024361?lang=en_us&edition=fundamental","pubTime":"2025-02-28 10:17","pubTimestamp":1740709061,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  received its first sales milestone payment of $50 million for the first year that the net sales of Rett syndrome drug Daybue exceeded $250 million in North America, according to a Friday filing with the Australian bourse.The company's Nasdaq-listed partner Acadia Pharmaceuticals reported $348.4 million net sales of the drug in the US in 2024, the filing said.The company will receive the second milestone payment from commercialization of the drug when net sales exceed $500 million, according to the filing.Neuren Pharmaceuticals shares fell 6% in afternoon trade Friday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2514365891","title":"BRIEF-Neuren Pharmaceuticals Receives First Daybue Sales Milestone Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2514365891","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514365891?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:23","pubTimestamp":1740705806,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Receives First Daybue Sales Milestone Payment Feb 28 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:NEUREN RECEIVES FIRST DAYBUE SALES MILESTONE PAYMENT OF US$50 MILLIONFurther company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU"],"gpt_icon":0},{"id":"2514631368","title":"Neuren Pharmaceuticals Ltd - Neuren Receives First Daybue Sales Milestone Payment of US$50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514631368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514631368?lang=en_us&edition=fundamental","pubTime":"2025-02-28 08:46","pubTimestamp":1740703560,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI2CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2514351570","title":"Neuren Pharmaceuticals Posts Lower 2024 Earnings as Revenue Drops","url":"https://stock-news.laohu8.com/highlight/detail?id=2514351570","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514351570?lang=en_us&edition=fundamental","pubTime":"2025-02-28 06:51","pubTimestamp":1740696690,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  reported Friday 2024 earnings of AU$1.0861 per diluted share, down from AU$1.2012 a year earlier.Analysts polled by Visible Alpha expected a diluted EPS of AU$0.95.Revenue from ordinary activities for the year ended Dec. 31, 2024, was AU$227.8 million, down from AU$240.1 million a year earlier. Analysts surveyed by Visible Alpha expected AU$194.8 million.Neuren anticipates earning royalties of AU$62 million to AU$67 million, assuming its global partner for trofinetide, Nasdaq-listed Acadia, meets its full-year net sales guidance of $380 million to $405 million for 2025, per the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU"],"gpt_icon":0},{"id":"2514591053","title":"Neuren Pharmaceuticals Posts 2024 EPS of AU$1.0861, Revenue of AU$227.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514591053","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514591053?lang=en_us&edition=fundamental","pubTime":"2025-02-28 06:37","pubTimestamp":1740695852,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Posts 2024 EPS of AU$1.0861, Revenue of AU$227.8 Million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU"],"gpt_icon":0},{"id":"2514318359","title":"Neuren Pharmaceuticals FY Net Income AUD 24.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514318359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514318359?lang=en_us&edition=fundamental","pubTime":"2025-02-28 06:28","pubTimestamp":1740695294,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nPLX3A8BF4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2514406188","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2514406188","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514406188?lang=en_us&edition=fundamental","pubTime":"2025-02-27 14:13","pubTimestamp":1740636810,"startTime":"0","endTime":"0","summary":"ASX investors finally caught another break this Thursday, with the S&P/ASX 200 Index (ASX: XJO) rising for only its second session in the past nine trading days. By the time the markets closed up shop","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/27/here-are-the-top-10-asx-200-shares-today-27-february-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","BK7095","QAN.AU","APE.AU","CGF.AU","BK7030","IRE.AU","BK7089","XJO.AU","BK7112","LTR.AU","BAP.AU","MPL.AU","RHC.AU","NEU.AU","BK7016","BK7086","BK7143","BK7504","BK7096","BK7113","BK7503","NHF.AU"],"gpt_icon":0},{"id":"2514812798","title":"Neuren Pharmaceuticals Partner Posts 97% Surge in Rett Syndrome Drug Sales in 2024; Neuren Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514812798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514812798?lang=en_us&edition=fundamental","pubTime":"2025-02-27 11:01","pubTimestamp":1740625283,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said its partner Acadia Pharmaceuticals reported 2024 net sales of $348.4 million in the US for its Rett syndrome drug, Daybue, according to a Thursday Australian bourse filing.The figure represents a 97% increase from 2023 and is close to the top end of Acadia's guidance of $340 million to $350 million, the filing said.Acadia, the company's partner for the development and commercialization of the drug, provided a 2025 guidance of between $380 million and $340 million for the US market.The company expects royalties of AU$56.2 million for 2024 and between AU$62 million and AU$67 million for 2025.The company's shares rose 8% in recent Thursday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU"],"gpt_icon":0},{"id":"2514032865","title":"Neuren Pharmaceuticals' (ASX:NEU) investors will be pleased with their massive 712% return over the last five years","url":"https://stock-news.laohu8.com/highlight/detail?id=2514032865","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514032865?lang=en_us&edition=fundamental","pubTime":"2025-02-25 13:18","pubTimestamp":1740460687,"startTime":"0","endTime":"0","summary":"For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock performs well, when investors win, they can win big. Just think about the savvy investors who held Neuren Pharmaceuticals Limited  shares for the last five years, while they gained 712%. And this is just one example of the epic gains achieved by some long term investors. Also pleasing for shareholders was the 12% gain in the last three months. It really delights us to see such great share price performance for investors.So let's assess the underlying fundamentals over the last 5 years and see if they've moved in lock-step with shareholder returns.While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuren-pharmaceuticals-asx-neu-investors-051807594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NEU","BK7096","BK7508","BK4109","NEU.AU"],"gpt_icon":0},{"id":"2513134277","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2513134277","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513134277?lang=en_us&edition=fundamental","pubTime":"2025-02-24 14:14","pubTimestamp":1740377653,"startTime":"0","endTime":"0","summary":"The S&P/ASX 200 Index (ASX: XJO) had a wild start to the week's trading this Monday. Overcoming a big opening loss, it finished 0.14% higher by the closing bell, breaking last week's five-day losing s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/24/here-are-the-top-10-asx-200-shares-today-24-february-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["NEU.AU","BK7141","BK7505","BK7148","BK7511","ALL.AU","BK7035","ANZ.AU","CBA.AU","ING.AU","BK7089","APA.AU","EVT.AU","XJO.AU","SEK.AU","BK7002","BK7078","BK7096","BK7135","BK7508","SGR.AU","NHF.AU"],"gpt_icon":0},{"id":"2513799917","title":"Neuren Receives New US FDA Rare Pediatric Disease Designation for Neurodevelopmental Disorder Drug Candidate; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513799917","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513799917?lang=en_us&edition=fundamental","pubTime":"2025-02-24 11:26","pubTimestamp":1740367584,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  received rare pediatric disease designation from the US Food and Drug Administration for its neurodevelopmental disorder drug candidate, NNZ-2591, in each of Pitt Hopkins syndrome and Angelman syndrome, according to a Monday filing with the Australian bourse.NNZ-2591 previously received the same designation for Phelan-McDermid syndrome.The Australian pharmaceutical company said it \"may be awarded a priority review voucher  if the Rare Pediatric Disease PRV program is reauthorized by the US Congress and NNZ-2591 receives marketing authorization for any of these indications.\"If awarded, a PRV can be used to obtain a priority review for a different product or sold to another sponsor.Neuren Pharmaceuticals' shares were up past 6% in recent Monday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","XKO.AU","NEU.AU","XAO.AU","XJO.AU","BK7096"],"gpt_icon":0},{"id":"2513762069","title":"BRIEF-Neuren Pharmaceuticals Gets Rare Pediatric Disease Designation From US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2513762069","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513762069?lang=en_us&edition=fundamental","pubTime":"2025-02-24 09:21","pubTimestamp":1740360101,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Gets Rare Pediatric Disease Designation From US FDAFeb 24 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:NEUREN RECEIVES RARE PEDIATRIC DISEASE DESIGNATION FROM US FDAFurther company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PD06H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2513976255","title":"BUZZ-Australia's Neuren Pharmaceuticals climbs to two-week high on US FDA designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2513976255","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513976255?lang=en_us&edition=fundamental","pubTime":"2025-02-24 09:05","pubTimestamp":1740359124,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharmaceuticals climbs to two-week high on US FDA designation** Shares of Australia's Neuren Pharmaceuticals NEU.AX rise as much as 6.3% to A$14.100, their highest levels since February 7** Stock on track for its second consecutive session of gains, if trend holds** The drug manufacturer gets rare paediatric disease designation from the U.S. Food and Drug Administration ** Designation for NNZ-2591 in each of Pitt Hopkins syndrome and Angelman syndrome - Neuren ** NNZ-2591 used for treatment of any traumatic brain injury    ** Stock has risen 11.6% so far this year, as of 0054 GMT  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nL3N3PF00W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU","BK7508","BK7096"],"gpt_icon":0},{"id":"2513630167","title":"Neuren Pharmaceuticals - Neuren Receives Rare Pediatric Disease Designation From US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2513630167","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513630167?lang=en_us&edition=fundamental","pubTime":"2025-02-24 06:20","pubTimestamp":1740349213,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250223:nFWN3PD06H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0}],"pageSize":16,"totalPage":7,"pageCount":1,"totalSize":106}]}}